pcvx-20260615
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 15, 2026
_____________________________________________
Vaxcyte, Inc.
(Exact name of Registrant as Specified in Its Charter)
_____________________________________________
| Delaware | 01-39323 | 46-4233385 | ||||||
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
825 Industrial Road Suite 300 San Carlos, California | 94070 | |||||||
| (Address of Principal Executive Offices) | (Zip Code) | |||||||
Registrant’s Telephone Number, Including Area Code: (650) 837-0111
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Common Stock, $0.001 par value per share | PCVX | The Nasdaq Stock Market LLC | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 15, 2026, Vaxcyte, Inc. (the “Company”) held its Annual Meeting of Stockholders. The following is a brief description of each matter voted upon at the meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.
1.The election of three nominees to serve as Class III directors until the Company’s 2029 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director’s death, resignation or removal. The following three Class III directors were re-elected by the votes indicated:
| For | Withheld | Broker Non-Votes | ||||||||||||||||||||||||||||||||||||
Olivier Brandicourt, M.D. | 116,370,183 | 16,643,897 | 4,354,403 | |||||||||||||||||||||||||||||||||||
Halley Gilbert, J.D. | 114,704,274 | 18,309,806 | 4,354,403 | |||||||||||||||||||||||||||||||||||
Grant Pickering, M.B.A. | 132,112,840 | 901,240 | 4,354,403 | |||||||||||||||||||||||||||||||||||
2. The ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The appointment was ratified by the votes indicated:
| For | Against | Abstain | |||||||||||||||
| 137,230,032 | 137,589 | 862 | |||||||||||||||
3. The approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers. The approval of the non-binding resolution on named executive officer compensation was approved by the votes indicated:
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 130,011,017 | 2,755,868 | 247,195 | 4,354,403 | |||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| VAXCYTE, INC. | |||||||||||
| Date: | June 16, 2026 | By: | /s/ Andrew Guggenhime | ||||||||
| Andrew Guggenhime President and Chief Financial Officer | |||||||||||